Covid-19: Govt forms high level task force for vaccine and drug testing

The task force would also form clinical cohorts which would focus on long term follow up of the disease and its management

Doctors, Coronavirus
The government will take a decision on the relaxations that would be given on lockdown restrictions in non-containment areas on April 20.
BS Reporter New Delhi
2 min read Last Updated : Apr 19 2020 | 5:36 PM IST
The government has formed a high level task force for vaccine and drug testing for Covid-19 on Sunday as the total death toll from the pandemic increased to 507 and the total cases reached 15,712. 

The main objective of the task force is to speed up national and international efforts towards vaccine development to treat Covid, Lav Aggarwal, joint secretary, health ministry said in the daily briefing.

The task force headed by member, NITI Aayog and principal scientific advisor to the Prime Minister will also include representatives of Ayush ministry, ICMR, department of biotechnology, drug controller general of India among others. 


Besides, the department of biotechnology would also act as a nodal agency “to identify the pathway for vaccine development, ,monitor progress of efforts at both national and international level in this area and provide government facilitation where needed. 

The task force would also form clinical cohorts which would focus on long term follow up of the disease and its management.

Government will collect bio-specimen which will form the basis for further drug and vaccine trials. 
“This is different from sample testing protocol,” Aggarwal added. 

The government will take a decision on the relaxations that would be given on lockdown restrictions in non-containment areas on April 20. 

As on Sunday, there are 54 districts where no new case has been reported in the last 14 days. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusLockdown

Next Story